Sheehy, SH; Duncan, CJ; Elias, SC; Biswas, S; Collins, KA; O'Hara, GA; Halstead, FD; Ewer, KJ; Mahungu, T; Spencer, AJ; Miura, K; Poulton, ID; Dicks, MD; Edwards, NJ; Berrie, E; Moyle, S; Colloca, S; Cortese, R; Gantlett, K; Long, CA; Lawrie, AM; Gilbert, SC; Doherty, T; Nicosia, A; Hill, AV; Draper, SJ (2012) Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PloS one, 7 (2). e31208. ISSN 1932-6203 DOI: https://doi.org/10.1371/journal.pone.0031208

Downloaded from: http://researchonline.lshtm.ac.uk/2352355/

DOI: 10.1371/journal.pone.0031208

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Figure S8. Relationship between total IgG ELISA titers and % GIA. (A) Spearman’s correlation of serum IgG ELISA titers against AMA1 for the 3D7 versus FVO alleles at day 84, n = 8. (B) Relationship between 3D7 strain % GIA and FVO strain % GIA using purified IgG at 10mg/mL.